I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Chronic Branch Retinal Vein Occlusion
Understanding Branch Retinal Vein Occlusion
BRVO occurs when a branch vein inside the retina becomes blocked, disrupting normal blood drainage and setting off a chain of events that can threaten vision. Understanding how this happens helps clarify why treatment and monitoring are so important.
Branch retinal vein occlusion happens when one of the smaller veins that drains blood from the retina becomes blocked. When blood cannot drain properly, pressure builds up in that section of the retina. This can lead to bleeding, swelling, and tissue damage in the affected area.
Most cases of BRVO develop at a crossing point where a retinal artery and a retinal vein share a common outer covering. When the artery stiffens due to atherosclerosis (hardening of the arteries), it compresses the vein running beneath it. This narrowing slows blood flow and creates conditions that promote clotting, which eventually leads to a full blockage.
Once a branch vein is blocked, two main problems can develop. First, fluid leaks from damaged blood vessels into the macula, the central part of the retina responsible for sharp, detailed vision. This is called macular edema (swelling within the macula). Second, the affected area of the retina may receive less oxygen-rich blood, a condition called ischemia, which can trigger further complications over time.
In some cases, the body creates alternative drainage pathways called collateral vessels, and the condition may partially resolve on its own. However, when the blockage persists or the retinal damage is significant, BRVO becomes chronic. This means that macular edema, ischemia, or both continue for months or even years. Ongoing monitoring and often repeated treatment are needed to preserve vision in these cases.
Who Is at Risk for BRVO?
BRVO is closely tied to cardiovascular health. Understanding the risk factors can help patients and their doctors take steps to manage both eye health and overall vascular wellness.
BRVO is one of the most common retinal vascular diseases. Research suggests it affects approximately 4 to 5 out of every 1,000 adults. The condition becomes more common with age and affects men and women at roughly similar rates.
Several health conditions raise the risk of developing BRVO, most of them related to blood vessel health and cardiovascular fitness.
- Uncontrolled high blood pressure, particularly elevated diastolic pressure (the lower number in a blood pressure reading)
- Cardiovascular disease, including a history of coronary artery disease or stroke
- Being overweight or obese
- Age over 50 years, with risk increasing with each decade of life
- A history of glaucoma, which is elevated pressure inside the eye
Controlling these risk factors is an important part of both preventing BRVO and reducing the chance of a vein occlusion developing in the other eye.
Research suggests that race may also play a role in risk. Studies in the United States have found that Black individuals have a meaningfully higher risk of developing BRVO compared to non-Hispanic white individuals. Age and elevated blood pressure are among the most consistently identified risk factors across large population studies.
Recognizing the Signs and Symptoms
BRVO does not always announce itself in obvious ways. Knowing what to look for, and understanding when to seek urgent care, can make a significant difference in outcomes.
The most typical symptom of BRVO is sudden, painless vision loss or blurriness affecting part of the visual field. This change can happen in an instant or worsen over several hours or days. Because the blockage affects only one branch of the retinal vein, often only a portion of the visual field is involved. Some people notice a blurry or dark area in their vision, while others experience a more widespread decline in clarity.
If the blocked vein supplies an area of the retina away from the macula, BRVO may cause no noticeable symptoms at all. The condition can go undetected for a long time and may only be discovered during a routine dilated eye examination. This is one of the key reasons why regular eye exams are so important for anyone over 50 or for those with known cardiovascular risk factors.
In chronic cases, BRVO can trigger the growth of abnormal new blood vessels on the retinal surface, a process called neovascularization. These fragile vessels can rupture and bleed into the vitreous (the clear gel filling the inside of the eye), causing sudden new floaters or a darkening of vision. In some patients, floaters from this type of internal bleeding are the first noticeable symptom if the original vein occlusion went undetected.
How BRVO Is Diagnosed
Accurate diagnosis of BRVO requires a thorough retinal evaluation using several specialized tools. Our retina specialists use a combination of clinical examination and advanced imaging to fully assess the extent of the condition.
A retina specialist will begin with a comprehensive dilated eye examination. Special drops are used to widen the pupil so the back of the eye can be seen in full detail. In BRVO, the specialist typically identifies a characteristic pattern of retinal hemorrhages (bleeding) that follows the distribution of the blocked vein. This pattern often appears as a wedge or fan shape, with the point of the wedge at the arteriovenous crossing where the blockage occurred.
Optical coherence tomography, known as OCT, is a noninvasive imaging test that creates detailed cross-sectional images of the retina. OCT is especially valuable for detecting and precisely measuring macular edema. It reveals exactly how much fluid has accumulated in the retinal layers. Our specialists rely on OCT at nearly every follow-up visit to track how the retina responds to treatment and to guide decisions about when additional injections are needed.
Fluorescein angiography involves injecting a special dye into a vein in the arm. As the dye travels through the retinal blood vessels, a camera captures a rapid series of photographs. This test reveals the location and extent of the blocked vein, areas of reduced blood flow, and any leaking vessels. It is also the primary method used to identify neovascularization, the abnormal new blood vessel growth that signals a serious complication of chronic BRVO.
Because BRVO is closely linked to cardiovascular health, our specialists often recommend blood pressure monitoring and coordination with a primary care physician. Blood tests to evaluate cholesterol, blood sugar, and other cardiovascular risk markers may also be ordered. Addressing these underlying conditions is a critical component of the overall care plan for chronic BRVO.
Treatment Options for Chronic BRVO
Treatment for chronic BRVO focuses on reducing macular edema, preserving vision, and preventing serious complications such as neovascularization. The right approach depends on each patient's individual situation and how the retina responds over time.
Anti-VEGF therapy is the first-line treatment for macular edema caused by BRVO. VEGF stands for vascular endothelial growth factor, a protein that promotes abnormal blood vessel growth and fluid leakage in the retina. These medications are injected directly into the vitreous cavity of the eye in a procedure called an intravitreal injection, and several FDA-approved options are currently available for treating macular edema related to retinal vein occlusion.
- Ranibizumab (Lucentis), approved for retinal vein occlusion, typically given monthly
- Aflibercept (Eylea), approved for BRVO, given every four to eight weeks after initial loading doses
- Faricimab (Vabysmo), a bispecific antibody that blocks both VEGF-A and angiopoietin-2, approved for retinal vein occlusion
- High-dose aflibercept (Eylea HD), a newer formulation designed to allow longer intervals between treatments
- Bevacizumab (Avastin), used off-label for retinal conditions and typically given every four to six weeks
A retina specialist will recommend the most appropriate medication based on each patient's individual circumstances, including prior treatment response, scheduling needs, and insurance coverage.
When chronic BRVO leads to neovascularization, scatter laser photocoagulation may be recommended. This thermal laser treatment is applied to the affected area of the retina and works by reducing the retina's demand for oxygen, which helps stop the growth of abnormal new blood vessels. Research has shown that scatter photocoagulation significantly reduces complications related to neovascularization in BRVO patients. This treatment is typically used alongside anti-VEGF therapy when neovascularization develops.
For patients who do not respond adequately to anti-VEGF therapy, or who have difficulty maintaining a frequent injection schedule, steroid-based treatment may be considered. A dexamethasone implant (Ozurdex) is a small, biodegradable device placed inside the eye that slowly releases anti-inflammatory medication over several months to reduce macular edema. Steroid treatments carry a higher risk of elevated eye pressure and cataract formation, so our specialists carefully weigh the benefits and risks for each individual patient before recommending this approach.
Several biosimilar medications have been approved to treat macular edema from retinal vein occlusion. Biosimilars are medications that are highly similar to existing FDA-approved anti-VEGF drugs and are designed to deliver equally effective treatment. Our specialists can help determine whether a biosimilar is an appropriate option based on clinical factors and a patient's overall treatment plan.
What to Expect During Treatment
Understanding what treatment involves can ease anxiety about the process. Our team is focused on making every visit as comfortable and informative as possible.
Intravitreal injections are performed in our office. The eye is numbed with anesthetic drops, and the surface is cleaned with an antiseptic solution. A very fine needle is then used to inject the medication into the vitreous cavity at the back of the eye. The procedure takes only a few minutes. Most patients feel mild pressure or brief discomfort during the injection, and temporary floaters, mild redness, or a gritty sensation afterward are common and typically resolve within a day or two.
Chronic BRVO often requires multiple injections over time. Most anti-VEGF treatment plans begin with monthly loading doses to bring macular edema under control. After this initial phase, the interval between injections may be extended based on how the retina responds. Newer agents, including high-dose aflibercept and faricimab, offer the possibility of longer intervals between treatments, which can make ongoing care more manageable. OCT imaging at each visit guides the decision about whether additional treatment is needed.
Many patients with chronic BRVO experience meaningful improvement in vision with prompt and consistent treatment. The degree of improvement depends on how long macular edema has been present, how much ischemia has developed, and how quickly treatment was started. Some patients achieve significant vision gains, while others may stabilize their vision and prevent further decline. A complete return to pre-BRVO vision is not guaranteed for every patient, and outcomes vary from person to person.
Living Well With Chronic BRVO
Managing chronic BRVO extends beyond eye injections. Taking an active role in your cardiovascular health and staying alert to changes in your vision are important parts of long-term care.
Because BRVO is closely tied to cardiovascular health, managing underlying medical conditions is essential. Controlling high blood pressure is the single most important modifiable step, as hypertension is the leading risk factor for retinal vein occlusion. Working with a primary care physician to maintain healthy blood pressure, cholesterol, and blood sugar levels can reduce the risk of future vascular events in the eye or elsewhere in the body.
Healthy lifestyle choices support overall vascular health and may help reduce the risk of BRVO worsening or developing in the other eye.
- Maintain a healthy weight through balanced nutrition and regular physical activity
- Follow a heart-healthy diet rich in fruits, vegetables, whole grains, and lean proteins
- Avoid smoking, as tobacco use causes lasting damage to blood vessels throughout the body
- Take all prescribed medications for blood pressure and cholesterol as directed
- Attend all scheduled follow-up appointments with your retina specialist
Patients with chronic BRVO should stay alert to changes in their vision between appointments. Using an Amsler grid (a simple chart with a pattern of horizontal and vertical lines) at home can help detect early shifts in central vision. If new symptoms appear, such as increased blurriness, new floaters, or a spreading dark area in the visual field, it is important to contact a retina specialist promptly. Early detection of complications like neovascularization leads to more effective treatment.
When to See a Retina Specialist
Knowing when to seek care, and recognizing when a symptom is an emergency, is a key part of managing chronic BRVO safely.
Certain symptoms should be treated as a medical emergency. Seek immediate evaluation if you notice any of the following.
- A sudden increase in floaters or a shower of new floaters
- Flashes of light in your vision
- A curtain or shadow spreading across part of your visual field
- Sudden, significant vision loss in one eye
These symptoms can indicate a retinal tear, retinal detachment, or vitreous hemorrhage, all of which require prompt treatment to prevent permanent vision loss.
Even when chronic BRVO appears stable, regular monitoring appointments remain essential. Our specialists use OCT and other imaging tools to check for macular edema recurrence and signs of neovascularization. The frequency of visits depends on the severity of the condition and the treatment plan in place. During active treatment, visits may occur every few weeks, while patients on extended injection intervals may be seen every few months.
If vision continues to decline despite treatment, or if you have concerns about your current care approach, seeking a second opinion from another retina specialist is a reasonable step. Chronic BRVO can be complex, and treatment strategies may differ between providers. Getting additional perspective can help confirm that the most appropriate plan is in place for your specific situation.
Frequently Asked Questions
Here are answers to some of the most common questions we hear from patients managing chronic BRVO.
BRVO most often affects one eye at a time and does not spread directly from one eye to the other. However, because the underlying causes, such as arterial stiffening and high blood pressure, affect blood vessels throughout the entire body, the second eye faces a meaningfully elevated risk of developing its own vein occlusion over time. Regular monitoring of both eyes and consistent management of cardiovascular risk factors are the most effective defenses against this possibility.
Treatment duration varies significantly from patient to patient. Some people require injections for several months, while others need ongoing treatment for years. At each visit, OCT imaging guides the decision about whether additional treatment is needed, meaning the schedule is based on what the retina shows rather than a fixed calendar. Newer anti-VEGF medications may allow for longer intervals between injections, making ongoing care more manageable over time.
Currently, there is no single treatment that permanently resolves chronic BRVO. The venous blockage often persists even when macular edema is well controlled, and fluid can return after treatment pauses. The goals of care are to control leakage, preserve as much vision as possible, and prevent serious complications such as neovascularization. Consistent monitoring and retreatment as needed are a standard and expected part of managing this condition over the long term.
Healthy lifestyle changes address the cardiovascular factors that contributed to BRVO, but they cannot substitute for the medical treatment your retina specialist prescribes. Decisions about whether to continue, pause, or adjust injections are based on what OCT imaging shows in the retina at each visit, not on lifestyle changes alone. Making healthy improvements is strongly encouraged and supports long-term vascular health, but it is important to continue all scheduled appointments and follow your treatment plan regardless of how you feel overall.
Without treatment, persistent macular edema can cause progressive, lasting damage to central vision. Over time, fluid accumulation harms the delicate retinal cells needed for reading, driving, and recognizing faces. Untreated ischemia can also stimulate neovascularization, which may lead to vitreous hemorrhage (internal bleeding in the eye), tractional retinal detachment (where scar tissue pulls the retina away from the back of the eye), and neovascular glaucoma (a severe form of elevated eye pressure caused by abnormal vessel growth).
Many patients continue driving and working throughout treatment, though this depends on how much vision has been affected and in which eye. On the day of an injection, temporary blurring from the procedure itself or from dilating drops may make driving difficult, so arranging transportation for those visits is advisable. Your retina specialist can offer specific guidance based on your visual acuity and the demands of your daily activities.
Schedule Your BRVO Evaluation
If you have been diagnosed with branch retinal vein occlusion, or if you are experiencing changes in your vision, our team is ready to help. New England Retina Associates provides fellowship-trained retina care to patients throughout Connecticut, with multiple convenient office locations and the advanced diagnostic technology needed to guide every stage of treatment. We welcome both self-referred patients and those referred by their eye doctor, and we are available for urgent evaluations when time is of the essence.
30 Years of Care & Commitment
